QLH2405

QLH2405 is an investigational humanized monoclonal antibody developed by Qilu Pharmaceutical for the treatment of Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. The drug is designed to target and facilitate the clearance of amyloid-beta (Aβ) proteins, which aggregate into plaques in the brains of patients with Alzheimer's and are a primary driver of neurodegeneration. By reducing the Aβ burden, QLH2405 aims to slow the progression of cognitive and functional decline. It is currently being evaluated in Phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics following subcutaneous administration in both healthy volunteers and patients with early-stage Alzheimer's disease.